AIHealthTech Insider: Issue #127
November 16, 2026
Illustrations in this issue are AI-generated.
Hello,
What if doctors could learn what a kidney stone was made of—even without the stone itself?
Mayo Clinic researchers used AI to look for clues in a 24-hour urine collection.
Also this week: simpler breast imaging, childhood brain patterns, a new stroke-prevention pill and an FDA GLP-1 warning.
For education, not medical advice.
☕ A little AI, a little trust...
Your doctor says, “I had AI take a second look at your test results.”

What's your first reaction?
👇 Later in this issue: What the FDA’s GLP-1 warning means—and which symptoms need immediate attention.
🔬 The Big Story
What can urine reveal about a missing kidney stone?
Mayo Clinic’s November 12 announcement describes an AI model that predicts kidney-stone composition using age, sex and results from a 24-hour urine collection.

Researchers developed it using data from more than 13,000 patients, then evaluated it on 1,653 additional patients.
The model correctly predicted stone composition in 73% of patients, compared with 33% using a conventional urine-based calculation.
Why it matters: Knowing a stone’s composition helps guide treatment and prevention. But patients don’t always have a stone available for laboratory analysis.
The catch: The model is designed to supplement existing tests, not replace them.
New here? Join 1,500+ readers getting one carefully sourced AI-healthcare briefing every Monday—written in plain English, without the hype.
🤎 Sponsored
Morning Matcha, Daytime Hydration: Your Two-Drink Glow Routine
A warm matcha in the morning. B·T Fountain in cold water through the day. Pique's Radiant Skin Protocol turns two familiar moments into a daily beauty-from-within routine for hydrated-looking skin.
Sun Goddess Matcha is organic, ceremonial-grade matcha from Kagoshima, Japan, with naturally occurring caffeine and L-theanine for calm, sustained energy. B·T Fountain adds ceramides, hyaluronic acid and electrolytes to support skin moisture and a dewy-looking complexion.
Studies on the ceramides in B·T Fountain reported skin hydration improvements of up to 37% and elasticity improvements of up to 36% over two months.*
Get 25% off all new subscriptions, plus free Holiday Chais on orders $80+, through November 29. Backed by a 90-day money-back guarantee.
⚡Research to Watch
Could a simpler ultrasound sensor help find breast lumps?
A November 15 study in Scientific Reports, a Nature Portfolio journal, tested AI analysis of signals from a single ultrasound sensor.

Researchers enrolled 200 patients scheduled for breast surgery, developing the models with 131 patients and evaluating them on the remaining 69.
The models distinguished areas containing a mass from normal breast tissue.
Why it matters: The work explores a possible route toward simpler breast-imaging technology.
The catch: Researchers still need to test the approach in women without known breast lesions before considering it for screening. It is not a replacement for mammograms.
🤎 Sponsored
This Plant-Derived Sleep Support is On Sale Now
If you’re one of the one-in-three adults who don’t get enough sleep, CBD can help. CBD works with your body to support sleep without causing next-morning drowsiness.
And one of the most-trusted brands for CBD, CBDistillery, isn’t waiting for Black Friday! Our readers can take 30% off with code BF30.
🧠 Brain in Brief
ADHD and anxiety don’t always follow separate patterns
What if two children with the same diagnosis have very different underlying brain patterns?
In a November 10 announcement, Stanford Medicine described how researchers used AI to identify three brain-pattern groups among children with ADHD, anxiety or both.

The groups crossed traditional diagnostic categories. Researchers also checked their findings in a separate group of 224 children.
Why it matters: These patterns could help researchers investigate why children with the same diagnosis respond differently to treatment.
The findings are a starting point for future research—not a new diagnostic test.
🤎 Sponsored
CBDistillery is celebrating a decade of helping customers find relief, relaxation and better sleep. Our readers can save 30% with code BF30, now through Black Friday.
🌿 Worth Knowing
Taking a GLP-1 medicine? Read the new FDA warning
On November 9, the FDA required updated warnings about a potential increased risk of NAION, a rare eye condition that can cause sudden, painless and sometimes permanent vision loss.

The labeling requirement covers all GLP-1 medicines, including Ozempic, Wegovy, Mounjaro and Zepbound.
Putting the risk in perspective: Across 126 clinical trials, the FDA found:
6.4 NAION cases per 100,000 person-years among GLP-1 users.
3.8 cases per 100,000 person-years in comparison groups.
The honest part: This is a labeling change, not a recall. The potential complication is rare.
What to know: Seek immediate medical attention for sudden vision loss, blurred vision or missing areas of vision. Discuss medication decisions with your healthcare professional.
Can a new pill help prevent a second stroke?
On November 9, the FDA approved Sunharbo (asundexian) for certain stroke and mini-stroke survivors.

In a trial involving 12,327 adults, adding the pill to standard antiplatelet therapy reduced ischemic stroke risk by 26% relative to placebo.
Why it matters: A new option for preventing repeat strokes, although bleeding risks remain, especially in adults over 75 and during the first 90 days.
One useful question this week
When a headline says AI “found” something, ask:
Did it identify a pattern—or help patients get better?
Both matter. They tell us different things.
Know someone who enjoys health research without the jargon? Forward this issue.




